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Abstract
Background: Cost is a vital component for people with chronic diseases as treatment is expected to be long or
even lifelong in some diseases. Pharmacist contributions in decreasing the healthcare cost burden of chronic
patients are not well described due to lack of sufficient evidences worldwide. In developing countries like Nepal,
the estimation of direct healthcare cost burden among newly diagnosed diabetics is still a challenge for healthcare
professionals, and pharmacist role in patient care is still theoretical and practically non-existent. This study reports
the impact of pharmacist-supervised intervention through pharmaceutical care program on direct healthcare costs
burden of newly diagnosed diabetics in Nepal through a non-clinical randomised controlled trial approach.
Methods: An interventional, pre-post non-clinical randomised controlled study was conducted among randomly
distributed 162 [control (n = 54), test 1 (n = 54) and test 2 (n = 54) groups] newly diagnosed diabetics by a
consecutive sampling method for 18 months. Direct healthcare costs (direct medical and non-medical costs) from
patients perspective was estimated by ‘bottom up’ approach to identify their out-of-pocket expenses (1USD = NPR
73.38) before and after intervention at the baseline, 3, 6, 9 and 12 months follow-ups. Test groups’ patients were
nourished with pharmaceutical care intervention while control group patients only received care from physician/
nurses. Non-parametric tests i.e. Friedman test, Mann–Whitney U test and Wilcoxon signed rank test were used to
find the differences in direct healthcare costs among the groups before and after the intervention (p ≤ 0.05).
Results: Friedman test identified significant differences in direct healthcare cost of test 1 (p < 0.001) and test 2
(p < 0.001) groups patients. However, Mann–Whitney U test justified significant differences in direct healthcare cost
between control group and test 1 group, and test 2 group patients at 6-months (p = 0.009, p = 0.010 respectively),
9-months (p = 0.005, p = 0.001 respectively) and 12-months (p < 0.001, p < 0.001 respectively).
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Conclusion: Pharmacist supervised intervention through pharmaceutical care program significantly decreased
direct healthcare costs of diabetics in test groups compared to control group and hence describes pharmacist’s
contribution in minimizing direct healthcare cost burden of patients.
Keywords: Diabetes mellitus, Healthcare costs, Intervention, Nepal, Pharmacists, Pharmaceutical care, Randomised
controlled trial
Background
Cost is a vital component for people with chronic diseases
as treatment is expected to be long, even life-long in many
cases. Pharmacist contributions in decreasing the health-
care cost burden of chronic patients are not well described
due to lack of sufficient evidences worldwide. Direct
healthcare costs (DHCs) are the “actual monetary expend-
iture used in treating or coping with a disease” [1]. In a
broader sense, the direct healthcare cost is the expend-
iture spent for detection, treatment, rehabilitation and
care of a disease [2]. Distinguishing the definition of cost
from price, “cost is a function of the inputs (labour, con-
sumable goods, depreciation, etc.) required to produce a
particular service” while “price is a function of what is paid
in the market place” [3]. Due to the chronic nature of dia-
betes, it is associated with a substantial impact on the
healthcare cost of patients2with the largest proportion at-
tributed to treatment cost among other components of
direct cost of diabetes [1, 4]. The global estimation of dir-
ect healthcare expenditure for people with diabetes is
about USD 153 billion per year [5].
In Nepal, where healthcare services are poor [6] and not
streamlined, people have difficulty in accessing the health-
care services most of the time. Furthermore, in absence of
government and private healthcare insurance coverage,
patients pay from their pocket to avail the acquired
healthcare services, which increase their out-of-pocket ex-
penses and make the treatment unaffordable to them. This
result in a delay in disease diagnosis and early episodes of
complications that may lead to frequent hospitalization
and increased prescription cost with subsequent effects on
other components of the direct cost domain [7]. Pharma-
cist role in patient care is still theoretical and practically
non-existent in Nepal resulting in huge healthcare cost
burden on patients. This study reports the impact of
pharmacist-supervised intervention through pharmaceut-
ical care program on direct healthcare costs of newly diag-
nosed diabetics in Nepal.
Methods
Study design
An interventional, pre-post non-clinical randomised
controlled trial among the control group (CG), test 1
group (T1G) and test 2 group (T2G) with three treat-
ment arms was conducted to explore the impact of
pharmacist-supervised pharmaceutical care intervention
on direct healthcare cost of newly diagnosed diabetics at
the Manipal Teaching Hospital, Pokhara, Nepal for
18 months (July 2010 to December 2011). The study
was approved by the Research and Ethics Committee of
Manipal Teaching Hospital, Nepal [8].
Study population
Newly diagnosed type 1 and type 2 diabetes mellitus pa-
tients of aged 16 years and above were selected. Pregnant
women, mentally incompetent patients, patients not will-
ing to participate and did not come at their first follow-up
were excluded from the study. Written consent was taken
from patients participating in the study. However, in case
of minors, parental consent was sought and obtained.
Sample and sampling technique
Sample size was calculated by using a finite population cor-
rection formula [9]. Diabetes prevalence of 9 % was taken
as the calculation factor from previous studies [10, 11]. The
Z value was set at 1.96, with a 95 % of confidence interval
and 5 % as margin of error. The calculated sample size was
125 patients. A drop-outs margin of 30 % was taken from
previous studies [12, 13] and added to the sample to
achieve the final targeted sample size of 162 patients. The
targeted sample was achieved by a consecutive sampling
method (based on time capsule frame) over 6 months dur-
ation (July 2010 to December 2010) [14]. The randomisa-
tion of 162 patients was done by 1:1:1 in three parallel
groups [CG (n = 54), T1G (n = 54) and T2G (n = 54)] with-
out disturbing the sequence of randomisation [15]. Ten
patients (CG = 4; T1G = 3 and T2G = 3) did not
complete their first assessment follow-up (3-months)
and therefore, further study was carried out with 152
patients [CG (n = 50), T1G (n = 51) and T2G (n = 51)] [8].
Study tools
Study tools were prepared in the Nepali language due to
language fluency and barriers to the English language
among most of the patients visiting the hospital. Socio-
demography form was used to collect the patients’
demographic characteristics. Direct healthcare costs
documentation form was used to analyse the cost in-
curred by the patients in diabetes management during
study period. Diabetes information booklet, diabetes
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complication chart and diabetic food chart were educa-
tional materials to improve the patients’ awareness about
diabetes and its management. A diabetic kit (including
glass tubings, chart of human anatomy with circulatory
system, daily medication calendar and calendar of anti-
diabetic medicines) was made especially for T2G (PC +
Diabetic kit group) patients to explain about anatomical
and physiological relationship of diabetes and its impact
on physiological system. The intention to use diabetic
kit only in T2G patients was to identify whether an extra
demonstration of diabetic kit would increase patient’s
understanding about diabetes and assist them for better
disease control. This extra initiative might bring remark-
able differences in direct healthcare cost burden of pa-
tients between T1G and T2G [8].
Estimation of direct medical and non-medical costs of
patients
The direct healthcare costs estimation (direct med-
ical and non-medical costs) from the patient’s per-
spective was done by a ‘bottom up’ approach [16] to
calculate their out-of-pocket expenses in managing
their diabetes during the study period (12-months).
The ‘bottom-up’ approach is based on the cost of in-
dividual units of service provided. The ‘bottom-up’
approach in fact starts from a selected subpopulation
with the actual disease and all the costs associated
with the disease is collected and extrapolated to the
national level [17].
Patient’s direct healthcare costs were estimated be-
fore and after pharmacist-supervised pharmaceutical
care intervention at the baseline and 3, 6, 9 and 12
months’ follow-ups respectively. Direct healthcare costs
incurred by patients at baseline and each follow-up are
the total sum of direct medical and non-medical costs.
Direct medical costs comprised of various cost-
variables including patient registration cost, cost for
emergency care, lab investigation cost, drug(s) cost and
cost of hospitalization and in-patient care. However,
direct non-medical costs include transportation cost,
meal cost on the way to hospital [1, 18] and dietary
management cost during investigation in hospital. In-
formation related to direct medicals cost was taken
from patient’s medical record (bills and prescriptions,
etc.) and hospital rate lists for different services.
To calculate direct medical costs on patient is multi-
plying the number of each service/care provided by the
unit cost of each service/care. For laboratory investiga-
tions, the number of laboratory tests performed was
multiplied by the unit cost of each test. However, the
calculation of drug cost(s) was done by multiplying the
number of dose by the unit price of the drug and the
resulting total costs was then multiplied by duration of
therapy to obtain the total drug costs. However, direct
non-medical cost estimation was done on the basis of
information collected from patients and their relatives
with regard to transportation cost, meal cost on the way
to hospital (to and fro) and dietary management cost on
each visit to the hospital.
Patients were asked to maintain a copy of all the bills
and prescriptions related to their treatment to ensure
the maximum accuracy of cost estimation. The calcula-
tion of DHCs at each follow-up covered direct medical
and non-medical costs of patient between the two
follow-ups (e.g. direct healthcare costs at 3-months will
be the sum of direct medical and non-medical costs be-
tween baseline and 3-months period and so on). All the
information related to direct healthcare costs were
documented in a pre-designed direct healthcare cost
documentation form.
Pharmacist intervention among diabetes patients
Pharmacist had made an attempt to minimize direct
healthcare cost burden of diabetics by improving their
understanding about diabetes. Pharmacist led interven-
tion was done among the patients of test groups (T1G
and T2G). Education and counselling about different as-
pects of diabetes and its management and, the correct
use of antidiabetic medications were the important in-
formation covered by the pharmacist during the inter-
vention. Patients from the test groups received the
information about meaning of diabetes, its types, sign
and symptoms, reasons for high blood glucose, risk
factors of diabetes, different short term and long term
complications of diabetes and role of pharmacological
(anti-diabetic medication) and non-pharmacological
(lifestyle modification, diet and exercise) measures in
management of diabetes from pharmacist. Besides this,
test groups patients were also taught about how to ad-
minister insulin by using insulin pen or insulin syringe
(if insulin was prescribed in therapy) and trained regard-
ing the use of glucometer for self-monitoring of blood
glucose (SMBG) at home. Medication envelopes were
used to dispense the prescribed medication (s) to the
patients.
In addition to it, the test 2 group patients received the
demonstration of diabetic kit components such as glass
tubing’s showing the change in the viscosity pattern of
blood among diabetic and non-diabetic patients and the
impact of increased sugar on the blood flow in different
organ system with emphasis of blood coagulation and
obstruction in blood flow in blood vessels in diabetes.
Chart of human anatomy with circulator system was de-
scribed to make the patients aware to locate the different
organ system in the body and the supply of blood to
these organs via blood vessels. Special focus was given to
those organs which are mainly affected in diabetes i.e.
cardiac system, renal system, eye and brain. They were
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also explained about the location of pancreas and its role
in diabetes. Daily medication calendar and anti-diabetic
medicine calendar were used to enhance the patients’
knowledge and compliance about the use of anti-
diabetic medication in diabetes management [8].
Statistical analysis
The direct healthcare costs of patients from three groups
were calculated at the baseline, 3, 6, 9 and 12 months’
follow-ups. Data was entered in SPSS version 16 and de-
scriptive analysis was done as required for data analysis.
Data was skewed (p < 0.05) on Kolmogorov-Smirnov
test. Non-parametric tests i.e. Friedman test, Mann–
Whitney U test were used to find out the differences be-
tween dependent and independent variables within and
between the groups before and after the interventions
respectively. The Wilcoxon signed rank test was used for
pre- and post-comparison within the groups. Post hoc
analysis with Wilcoxon signed rank test was used to
find out in which follow-up the significant differences
actually occurred in the group at a new p-value of
≤0.005 after Bonferroni adjustment. A significance level
of p ≤ 0.05 was used in all analyses.
Results
Socio-demography of patients
The study enrolled 162 patients. The mean age (in years)
of the patients was 49.14 ± 12.56. Males were greater in
number (n = 106, 65.43 %). The median monthly income
and inter-quartile range of the patients was Nepali ru-
pees (NPR) 10,000 [(9,000)-(16,000)] (1USD = 73.38
NPR). About 40.7 % patients were unemployed, 25.9 %
businessman, 18.5 % employed, 13.6 % pensioner and
1.2 % students in the study. The study found 30.9 % pa-
tients either primary educated or secondary educated
and, only 24 % and 14.2 % patients were non-educated
and tertiary educated respectively. There were no signifi-
cant differences in education level and health related
knowledge among the patients of three groups at base-
line. There were 92 % patients of non-vegetarian food
habits. Nearly 42.6 % and 57.4 % patients never had al-
cohol and smoking habits respectively. Type 2 diabetics
were found more (n = 156, 96.3 %) in the study [8].
Geometric changes in direct medical and non-medical
costs of CG, T1G and T2G patients at the baseline and
follow-ups
Descriptive analysis was done to calculate direct medical
and non-medical costs burden on diabetics and results
are presented in mean ± sd and median (IQR) cost. The
chief contributors of direct medical and non-medical
costs of the control and test groups’ patients were cost
of investigation, drug(s) costs, patient registration cost,
and transportation cost, dietary management cost
respectively. Pharmacist-provided intervention reduced
direct medical and non-medical cost burden on patients
in test groups with greater reduction in anti-diabetic
treatment cost in subsequent follow-ups (Table 1).
Direct healthcare costs (direct medical + non-medical
costs) of CG, T1G and T2G patients at baseline and
follow-ups
The median direct medical costs, the median direct
non-medical costs and the total median direct healthcare
costs of CG, T1G and T2G patients at the baseline and
follow-ups are mentioned in Table 2. The reduction in
cost variables attributed to increased cost of patients
could be achieved by successive counselling and diabetes
education related to diabetes care from the pharmacist,
which ultimately affected the direct medical and non-
medical costs of patients resulting in a substantial reduc-
tion in total direct healthcare cost of patients in both
test groups compared to control group in their follow-
ups (Table 2).
Direct healthcare costs comparison of patients at the
baseline and follow-ups within test groups (T1G and T2G)
Friedman test identified the significant differences in
DHCs of test 1 group (p < 0.001) and test 2 group
(p < 0.001) patients due to pharmaceutical care inter-
vention (Table 3).
However, it was difficult to explore from Friedman test
where the actual significant differences occurred in each
group on different occasions, which was resolved by
using post-hoc analysis with the Wilcoxon signed rank
test after Bonferroni adjustment applied (Table 4).
Comparison of direct healthcare costs between test
groups (T1G and T2G), and CG and test groups’ patients
Although there were differences in median direct health-
care costs between the test groups (T1G and T2G) over
time but differences were not statistically significant at
Mann–Whitney U-test. Moreover, the significant differ-
ences in direct healthcare cost between CG and T1G,
and T2G were noted at 6-months (p = 0.009, p = 0.010
respectively), 9-months (p = 0.005, p = 0.001 respectively)
and 12-months (p < 0.001, p < 0.001 respectively)
(Table 5).
Discussion
Diabetes is a very costly illness that creates a major im-
pact on patient's direct healthcare costs (out-of-pocket
expenses) [19]. The trend of increasing burden on pa-
tients’ out-of-pocket expenses is due to lack of patients’
focus on disease management in absence of their disease
awareness and self-care practices.
The major contribution in total median direct health-
care costs of patients was attributed to median direct
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Table 1 Geometric changes in direct medical and non-medical costs of CG, T1G, and T2G patients at the baseline and follow-upsa
Direct medical cost
Cost variables Groupsb Baseline 3-months (1st FU) 6-months (2nd FU) 9-months (3rd FU) 12-months (4th FU)
Mean cost
± sd
Median cost
(IQR)
Mean cost
± sd
Median cost
(IQR)
Mean cost
± sd
Median cost
(IQR)
Mean cost
± sd
Median cost
(IQR)
Mean cost
± sd
Median cost
(IQR)
Patient registration CG 30.00 ± .00 30 (30)-(30) 76.20 ± 29.82 60 (60)-(90) 94.80 ± 22.15 90 (90)-(120) 81.00 ± 34.41 90 (60)-(97.50) 90.60 ± 22.26 90 (90)-(90)
T1G 30.00 ± .00 30 (30)-(30) 102.94 ± 20.12 90 (90)-(120) 66.47 ± 19.26 60 (60)-(90) 50.58 ± 20.33 60 (30)-(60) 49.41 ± 20.63 60 (30)-(60)
T2G 30.00 ± .00 30 (30)-(30) 69.41 ± 23.61 60 (60)-(90) 67.05 ± 22.28 60 (60)-(90) 53.52 ± 20.18 60 (30)-(60) 41.17 ± 17.96 30 (30)-(60)
Emergency care
(if any)
CG T1G
T2G
0 0 0 0 0 0 0 0 0 0
Hospitalization and
in-patient care (if any)
CG 51.12 ±
264.08
0 (0)-(0) 0 0 16.00 ±
113.13
0 (0)-(0) 0 0 0 0
T1G 27.48 ±
139.55
0 (0)-(0) 0 0 0 0 0 0 0 0
T2G 19.44 ±
142.88
0 (0)-(0) 0 0 0 0 0 0 0 0
Investigations CG 406.20 ±
222.35
350 (313.25)-
(430)
464.60 ± 92.45 450 (400)-
(542.50)
462.88 ±
89.96
450 (440)-
(492.50)
445.46 ±
104.63
400 (400)-(455) 459.50 ±
114.59
450 (400)-(500)
T1G 413.29 ±
161.34
350 (340-460) 474.90 ± 88.20 455 (450)-(500) 425.92 ±
72.33
405 (400)-(450) 398.07 ±
72.60
400 (355)-(405) 385.05 ±
56.29
355 (350)-(400)
T2G 399.75 ±
116.60
350 (340)-(405) 435.49 ± 91.76 400 (400)-(450) 417.90 ±
82.49
400 (390)-(450) 398.68 ±
53.69
400 (355)-(405) 367.35 ±
34.19
350 (350)-(400)
Drug (s)
costc
ADD CG 211.40 ±
226.82
109 (45)-
(304.75)
1080.00 ±
869.36
870 (560)-
(1236.50)
869.48 ±
435.99
880 (584)-(995) 755.86 ±
302.69
760 (560)-
(978.50)
661.28 ±
294.93
650 (495)-
(884.70)
AntiHTN 50.14 ±
101.61
0 (0)-(77) 148.66 ±
366.41
0 (0)-(182) 250.34 ±
398.26
0 (0)-(650) 248.00 ±
310.34
0 (0)-(560) 253.58 ±
306.02
0 (0)-(540.75)
Others 132.12 ±
496.84
0 (0)-(73.50) 157.16 ±
541.23
0 (0)-(13.50) 182.06 ±
358.23
0 (0)-(91.75) 164.52 ±
389.07
0 (0)-(67.75) 154.90 ±
390.06
0 (0)-(54)
ADD T1G 216.75 ±
274.08
141 (47)-(316) 993.19 ±
838.77
761 (288)-(1544) 790.49 ±
840.25
480 (0)-(1222) 665.27 ±
538.23
508 (284)-(929) 436.21 ±
534.41
254 (48)-(692)
AntiHTN 33.11 ± 76.89 0 (0)-(6.25) 169.15 ±
353.51
0 (0)-(222) 166.39 ±
389.02
0 (0)-(0) 114.62 ±
234.93
0 (0)-(0) 84.64 ±
195.71
0 (0)-(0)
Others 82.85 ±
153.45
0 (0)-(110.75) 250.76 ±
720.28
0 (0)-(0) 172.31 ±
579.29
0 (0)-(0) 148.54 ±
506.22
0 (0)-(0) 121.29 ±
360.94
0 (0)-(0)
ADD T2G 158.42 ±
186.14
83.50 (20.50)-
(212)
1035.80 ±
669.29
1015 (480)-
(1500)
754.33 ±
856.70
350 (48)-(1269) 579.00 ±
798.76
367 (139)-(750) 315.47 ±
470.88
157 (0)-(413)
AntiHTN 33.48 ± 90.07 0 (0)-(0) 178.00 ±
309.62
0 (0)-(215) 121.29 ±
218.61
0 (0)-(277) 91.45 ±
210.78
0 (0)-(0) 73.07 ±
180.94
0 (0)-(0)
Others 64.70 ±
207.71
0 (0)-(0) 192.66 ±
509.89
0 (0)-(0) 151.86 ±
386.75
0 (0)-(54) 154.07 ±
536.24
0 (0)-(0) 112.96 ±
379.02
0 (0)-(0)
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Table 1 Geometric changes in direct medical and non-medical costs of CG, T1G, and T2G patients at the baseline and follow-upsa (Continued)
Direct non-medical cost
Cost variables Groupsb Baseline 3-months (1st FU) 6-months (2nd FU) 9-months (3rd FU) 12-months (4th FU)
Mean cost ±
sd
Median cost
(IQR)
Mean cost ±
sd
Median cost
(IQR)
Mean cost ±
sd
Median cost
(IQR)
Mean cost ±
sd
Median cost
(IQR)
Mean cost ±
sd
Median cost
(IQR)
Transport (round
trips)
CG 166.53 ±
314.99
54 (30)-(162.50) 233.36 ±
196.70
155 (87.50)-
(312.50)
112.34 ±
53.20
120 (69)-(150) 101.60 ±
49.29
100 (70)-(140) 125.32 ±
71.84
120 (78.75)-
(165)
T1G 110.38 ±
277.22
30 (24)-(85) 108.62 ± 62.76 100 (80)-(150) 117.54 ±
98.23
80 (50)-(160) 109.80 ±
100.45
80 (40)-(150) 108.33 ±
95.28
80 (48)-(120)
T2G 100.09 ±
176.45
40 (28.75)-(70) 116.82 ± 64.04 120 (60)-(200) 117.39 ±
77.31
100 (60)-(160) 113.07 ±
113.07
80 (48)-(120) 117.98 ±
154.49
80 (40)-(108)
Meal on the way to
hospital (round trip,
if any)
CG 1.85 ± 13.60 0 (0)-(0) 11.70 ± 29.06 0 (0)-(0) 6.24 ± 22.65 0 (0)-(0) 8.60 ± 24.05 0 (0)-(0) 7.10 ± 21.33 0 (0)-(0)
T1G 3.70 ± 27.21 0 (0)-(0) 8.56 ± 27.75 0 (0)-(0) 6.54 ± 18.77 0 (0)-(0) 5.86 ± 20.77 0 (0)-(0) 3.54 ± 10.07 0 (0)-(0)
T2G 2.22 ± 16.32 0 (0)-(0) 7.05 ± 20.20 0 (0)-(0) 3.88 ± 11.20 0 (0)-(0) 7.01 ± 23.35 0 (0)-(0) 7.25 ± 23.18 0 (0)-(0)
Dietary management
during investigation
CG 137.37 ±
293.93
60 (50)-(100) 147.00 ± 44.82 150 (120)-(200) 183.20 ±
100.21
180 (140)-(200) 157.50 ±
52.37
160 (120)-(200) 172.00 ±
30.10
170 (150)-(200)
T1G 111.12 ±
191.28
60 (60)-(80) 142.15 ± 34.13 150 (120)-(160) 123.03 ±
47.46
120 (80)-(150) 111.07 ±
59.27
90 (80)-(120) 114.31 ±
47.17
100 (80)-(150)
T2G 86.66 ±
145.06
60 (50)-(60) 162.64 ± 60.69 160 (120)-(200) 142.54 ±
57.37
140 (100)-(180) 131.07 ±
52.18
120 (100)-(150) 103.03 ±
44.83
100 (60)-(130)
a = costs were calculated in Nepali rupees (NPR) [Exchange rate: 1 USD = NPR 73.38]
b = CG = control group, T1G = test 1 group, T2G = test 2 group
c = ADD = antidiabetic drug, AntiHTN = antihypertensive, others = Lipid lowering agents, Anti anginal drugs, Vitamin B complex, Antibiotic, Proton pump inhibitors, Antihistaminic, Antiplatelet agent
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Table 2 Total direct healthcare costs (direct medical and non-medical costs) of CG, T1G and T2G patients at the baseline and follow-ups
Follow-
ups
Groupsb Direct medical costsa Direct non-medical costsa Total direct healthcare costs (Direct medical + non-medical costs)a
Mean cost ± sd Median cost (IQR) Mean cost ± sd Median cost (IQR) Mean cost ± sd Median cost (IQR)
Baseline CG 881.01 ± 1024.31 657 (445)-(879) 305.75 ± 557.60 129 (90)-(232) 1186.77 ± 1444.30 861 (583.75)-(1104.25)
T1G 803.50 ± 455.06 737 (468)-(944.50) 225.22 ± 379.79 92.50 (80)-(200) 1028.72 ± 667.85 914 (615)-(1144)
T2G 705.81 ± 450.93 567.50 (429)-(838) 188.98 ± 310.18 99 (80)-(150) 894.79 ± 660.23 712 (525.75)-(986.25)
3-months CG 1926.62 ± 1226.31 1714.50 (1234.75)-(2176.25) 392.06 ± 211.27 320 (243.75)-(492.50) 2318.68 ± 1247.24 2057.50 (1645)-(2527.75)
T1G 1990.96 ± 1180.94 1769 (1100)-(2452) 259.35 ± 80.69 240 (200)-(300) 2250.31 ± 1179.84 2071 (1350)-(2802)
T2G 1911.37 ± 1003.66 1733 (1146)-(2358) 286.52 ± 111.37 300 (198)-(360) 2197.90 ± 1043.56 2062 (1384)-(2673)
6-months CG 1875.56 ± 918.03 1712.50 (1235.50)-(2459) 301.78 ± 144.03 305 (218)-(360) 2177.34 ± 998.34 2080 (1467.25)-(2761.25)
T1G 1621.58 ± 1220.84 1037 (738)-(2142) 247.13 ± 129.06 200 (150)-(310) 1868.72 ± 1217.24 1410 (925)-(2327)
T2G 1512.45 ± 981.02 1309 (690)-(2020) 263.82 ± 119.56 255 (178)-(330) 1776.27 ± 1029.89 1543 (913)-(2263)
9-months CG 1694.84 ± 730.40 1609.50 (1192.50)-(2098.25) 267.70 ± 90.34 275 (200)-(320) 1962.54 ± 767.27 1894.50 (1376.25)-(2378.50)
T1G 1377.11 ± 723.19 1219 (753)-(1739) 226.74 ± 160.15 160 (128)-(320) 1603.86 ± 758.96 1374 (1104)-(1888)
T2G 1276.74 ± 935.41 947 (631)-(1586) 251.17 ± 169.73 200 (148)-(300) 1527.92 ± 951.75 1260 (925)-(2144)
12-months CG 1568.86 ± 565.84 1548 (1122.75)-(1866.75) 304.42 ± 92.58 307.50 (225)-(362.50) 1873.28 ± 587.99 1851.50 (1437.25)-(2272.25)
T1G 1076.62 ± 726.61 768 (500)-(1488) 226.19 ± 126.02 184 (140)-(252) 1302.82 ± 771.70 1020 (660)-(1833)
T2G 910.03 ± 650.91 620 (460)-(1116) 228.27 ± 193.20 180 (100)-(240) 1138.31 ± 682.27 900 (597)-(1455)
a = costs were calculated in NPR [Exchange rate: 1 USD = NPR 73.38]
b = CG = control group, T1G = test 1 group, T2G = test 2 group
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medical costs. The direct medical costs of patients in
present study were greatly occupied with investigation
costs followed by drug costs at baseline [5]. It was esti-
mated that the total median direct healthcare costs of
individual group at baseline was occupied by slightly
more than half of median direct medical costs, which
was further occupied by nearly one third of total median
medication cost in each group. This is higher than the
observation made from a study conducted in Italy [4].
Similarly, the dietary management costs and transporta-
tion costs were the main contributing components of
direct non-medical costs at baseline in the present
study.
Patients must be alert and proactive in managing their
diabetes to avoid the co-morbidities that may cause sig-
nificant out-of-pocket expenses of patients due to in-
creased medical and medication costs related to diabetes
and co-morbid conditions [19]. The out-of-pocket ex-
penses of patients can be minimised by improving their
health related outcomes. Pharmacist being an important
member of healthcare team can provide a good support
to patient in improving their health related outcomes
and hence minimizing their out-of-pocket expenses. It is
already evident from Asheville project in which authors
demonstrated the impact of pharmaceutical care on eco-
nomic outcomes in diabetes management [20]. There
was significant increase in out-of-pocket expenses of pa-
tients in three groups at 3 months due to increase direct
medical costs. The sudden increase in patients’ out-of-
pocket expenses was due to the high degree of glycaemia
that required frequent patient visits to the hospital
during the first 3 months of the initiation phase of treat-
ment to get the physician's consultation. This subse-
quently increased the costs of other components of
direct medical and non-medical domains with major im-
pact on drug costs, investigation cost, registration cost,
transportation cost and dietary management cost. To-
gether, this amplified the median direct healthcare costs
of patients in the three groups at 3 months. A rise in
out-of-pocket expenses may decrease or prevent the
health-seeking behavior of the patients and prevent them
from medication procurement [21].
Pharmacist led intervention reduced direct healthcare
costs burden of patients significantly in test groups at 6,
9 and 12 months’ follow-ups compared to control group
when tested by Mann–Whitney U-test. Similarly, few
studies from USA also described a reduction in total dir-
ect medical costs and per patient direct healthcare cost
due to pharmacist led intervention through pharmaceut-
ical care program [20, 22, 23]. The major reduction was
calculated in direct medical cost components such as in-
vestigation cost and prescription cost of patients [24].
This reduction could be due to improvement in gly-
caemic symptoms of patients that reduces their drug
prescription and frequency of investigations. Moreover, a
Colombian study also highlighted the reduction in med-
ical cost of those patients who were under the care of
pharmacist compared to control group patients [25].
Table 3 Direct healthcare costs comparison of patients at the
baseline and follow-ups within test groups (T1G and T2G)
Groups T1G (PC group) T2G (PC + Diabetic kit group)
Follow-ups Median cost (IQR) Median cost (IQR)
Baseline 914 (615)-(1144) 712 (525.75)-(986.25)
3-months (1st FU) 2071 (1350)-(2802) 2062 (1384)-(2673)
6-months (2nd FU) 1410 (925)-(2327) 1543 (913)-(2263)
9-months (3rd FU) 1374 (1104)-(1888) 1260 (925)-(2144)
12-months (4th FU) 1020 (660)-(1833) 900 (597)-(1455)
p-value* <0.001** <0.001**
*Friedman test applied
**Difference was significant at p ≤ 0.05 level (2-tailed)
Table 4 Differences in direct healthcare costs of patients in both test groups (T1G and T2G) over time
Follow-ups T1G (PC group) T2G (PC + Diabetic kit group)
Z- value p-value* Z-value p-value*
Baseline + 3-months -5.352 <0.001** -5.676 <0.001**
Baseline + 6-months -4.396 <0.001** -5.015 <0.001**
Baseline + 9-months -4.134 <0.001** -4.898 <0.001**
Baseline + 12-months -2.132 0.033 -2.531 0.010
3-months + 6-months -1.978 0.048 -2.235 0.025
3-months + 9-months -4.134 <0.001** -3.674 <0.001**
3-months + 12-months -4.387 <0.001** -5.408 <0.001**
6-months + 9-months -1.322 0.186 -1.429 0.153
6-months + 12-months -2.690 0.005** -3.890 <0.001**
9-months + 12-months -2.090 0.037 -4.218 <0.001**
* Wilcoxon signed rank test for paired data
**Difference was significant at p ≤ 0.005 level (2-tailed) after Bonferroni adjustment applied
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The median DHCs of patients in test groups decreased
significantly compared to control group due to reduction
in their median direct medical costs at 12 month follow-
up. Although, there were differences in median DHCs
(in Nepali rupees) of patients in both test groups
throughout the study period but it was not significant at
any of the follow-ups. The insignificant decrease in
median direct healthcare costs of patients in control
group compared to test groups could be due to the
doctor∕nurse provided care. The additional out-of-pocket
expenses on patients in the absence of government and
private health-insurance coverage1demands an urgent
need of various healthcare schemes(e.g. health-insurance
coverage) for the patients in developing countries like
Nepal in order to protect their domestic budget, that may
lead to improvement in their medication adherence and
decrease the risk of chronic complications.
Limitations of the study
Diabetes patients were selected from only one hospital
of the Kaski district in western Nepal and hence the
study findings may not be able to generalize to the entire
diabetic population of the country. The study estimated
the reduction in treatment costs but fail to analyse the
decrease in number of drug (s) per prescription of pa-
tient after the intervention. Similarly, the decrease in
number of patient visits to the hospital was also not
accounted. Furthermore, cost of pharmacist services was
not taken into account in present study as there was no
such cost taken by the hospital from the patient where
study was conducted.
Conclusion
Direct healthcare costs of patients were mainly attrib-
uted to direct medical costs but contribution of trans-
portation cost and dietary management cost cannot be
ignored in direct non-medical cost. Pharmacist-provided
intervention significantly decreased the direct healthcare
costs of patients in test groups during their follow-ups
with a greater reduction in drug costs and investigation
costs. However, reduction in direct healthcare costs
among control group patients was insignificant. The re-
duction in the direct healthcare costs of patients indi-
cates the benefits of pharmacist-provided counselling
and consultation through pharmaceutical care program
in diabetes patient care and hence indicates pharmacist
role and contribution in healthcare system.
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